Your list of analysts covering Amarantus Biosciences is incomplete. After listening to multiple Amarantus conference calls provided to me by former AMBS investors (thanks again for your support), the following analysts were identified on the calls. You will note that there were 4 analysts on the calls NOT on the lists of analysts you provided. They are identified in red. Par for the course with inadequate DD on your part. I would be happy to post the audio files from the conference calls if necessary.
I also included your name for the calls where you presented yourself as an analyst. All other callers who were private investors identified themselves as such. One has to wonder why you didn't identify yourself as a private investor. One could understand the mistake on the November 2013 call, where you posted you didn't know they would announce your company name on the call, or identify you as an analyst. This might have been your first investor conference call, but the call was posted on the AMBS board and the transcript of the call made available that listed you as an analyst. Yeah, okay, their mistake, right?
But on the September 2014 call you once again you identified yourself with your company name, knowing they would identify you as an analyst on the call. Why create the same "error" again unless it was intentional—you wanted to be identified as an analyst. Mistake the first time? Maybe. Mistake the second time? No one is buying that. The SEC is not likely to see it as a mistake repeated a second time one year later. I think they'll come to the same conclusion reached on this board.
April 2013 AMBS Conference Call
Jason Napodano — Zacks Investment Research
Matthew Margolis — OneMedPlace Global Investments
November 2013 AMBS Conference Call
Jason Napodano — Zacks Investment Research
John Petrosino — JWP Incorporated
April 2014 AMBS Conference Call
Jason Napodano — Zacks Investment Research
Nick Cooper — Edison Investment Research
Jeffrey Kraws — Crystal Research Associates
September 2014 AMBS Conference Call
Jason Napodano — Zacks Investment Research
John Petrosino — JWP Incorporated
Jolene Furdek — Edison Investment Research
The fact your name doesn't appear on your list of certified analysts means nothing. The four analysts I identified from the calls (but not on your list) are also FINRA licensed and were clearly interested in Amarantus. More evidence for the SEC looking into this matter. I would be concerned if I were in your shoes.
One other point. From listening to these calls and the numerous Amarantus corporate advisors, it was clear to me this company wasn't the scam you claim. They were very engaging and extremely knowledgeable in their respective fields of expertise. CEO Gerald Commissiong might have made bad choices in funding the company, but it was clear he assembled a top-notch team. I believe he was also on the right track with Todos Medical. But small companies face a lot of hurdles and neither company survived. I lost money in Todos and I own the decision to invest. I don't put all the blame on the CEO, as some do. Anyone who decides to invest 6-figures-plus in a penny stock company with zero revenue has only themselves to blame for that decision. They can either OWN IT, or act like a CRYBABY and blame others.
